Please ensure Javascript is enabled for purposes of website accessibility
Search
Accessibility Menu
ImmunoPrecise Antibodies Stock Quote

ImmunoPrecise Antibodies (NASDAQ: IPA)

$1.12
(-2.5%)
-$0.03
Price as of May 16, 2024, 3:57 p.m. ET

ImmunoPrecise Antibodies Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
IPA -62.03% -56.03% -15.15% -74%
S&P +29.16% +85.63% +13.17% +134%

ImmunoPrecise Antibodies Company Info

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.